David DeWorsop

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3862333/publications.pdf

Version: 2024-02-01

44 papers	2,554 citations	257357 24 h-index	265120 42 g-index
45 all docs	45 docs citations	45 times ranked	3226 citing authors

#	Article	IF	Citations
1	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 2005, 57, 594-608.	0.7	524
2	Gone to Pot Ã¢â‚¬â€œ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry, 2014, 5, 54.	1.3	235
3	Marijuana Legalization: Impact on Physicians and Public Health. Annual Review of Medicine, 2016, 67, 453-466.	5.0	147
4	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 60-67.	1.1	135
5	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry,the, 2019, 6, 35-45.	3.7	125
6	Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry, 2016, 79, 526-538.	0.7	113
7	Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports, 2014, 1, 115-128.	1.6	109
8	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open, 2020, 3, e204693.	2.8	103
9	Cannabinoids and Psychosis. International Review of Neurobiology, 2007, 78, 289-326.	0.9	83
10	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry, 2016, 79, 997-1005.	0.7	83
11	Medical Marijuana. JAMA - Journal of the American Medical Association, 2015, 313, 2431.	3.8	75
12	Lower Î²₂*-Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia. American Journal of Psychiatry, 2012, 169, 326-334.	4.0	59
13	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology, 2012, 37, 1036-1046.	2.8	58
14	Î”9-THC Disrupts Gamma (Î³)-Band Neural Oscillations in Humans. Neuropsychopharmacology, 2015, 40, 2124-2134.	2.8	57
15	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 2020, 212, 107993.	1.6	49
16	Glycine Site Agonists of the NMDA Receptor: A Review. CNS Neuroscience & Therapeutics, 1995, 1, 227-260.	4.0	46
17	The Psychosis-like Effects of Î”9-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. Biological Psychiatry, 2015, 78, 805-813.	0.7	44
18	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry, 2018, 84, 413-421.	0.7	43

#	Article	IF	Citations
19	Problems With the Medicalization of Marijuana. JAMA - Journal of the American Medical Association, 2014, 311, 2377.	3.8	40
20	Going deep into schizophrenia with artificial intelligence. Schizophrenia Research, 2022, 245, 122-140.	1.1	39
21	Cannabis and Driving. Frontiers in Psychiatry, 2021, 12, 689444.	1.3	36
22	Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers in Psychiatry, 2014, 5, 3.	1.3	34
23	Age-Related Change in 5-HT₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹C-GSK215083 PET. Journal of Nuclear Medicine, 2018, 59, 1445-1450.	2.8	34
24	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry, 2021, 26, 3192-3200.	4.1	32
25	Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls. NeuroImage: Clinical, 2019, 23, 101878.	1.4	31
26	GABA Deficits Enhance the Psychotomimetic Effects of Î”9-THC. Neuropsychopharmacology, 2015, 40, 2047-2056.	2.8	29
27	Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 176-183.	2.5	27
28	Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the â€œself-medicationâ€•hypothesis in schizophrenia. Schizophrenia Research, 2018, 194, 62-69.	1.1	26
29	Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. Drug and Alcohol Dependence, 2016, 163, 24-30.	1.6	23
30	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders, 2022, 303, 91-97.	2.0	22
31	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. NeuroImage, 2021, 237, 118167.	2.1	18
32	In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research - Neuroimaging, 2020, 295, 111007.	0.9	17
33	Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. Psychological Medicine, 2021, 51, 353-364.	2.7	17
34	Marijuana and Madness: Associations Between Cannabinoids and Psychosis. Biological Psychiatry, 2016, 79, 511-513.	0.7	13
35	Differential Cognitive Performance in Females and Males with Regular Cannabis Use. Journal of the International Neuropsychological Society, 2021, 27, 570-580.	1.2	6
36	Medical Marijuana. Journal of Clinical Psychiatry, 2019, 80, .	1.1	5

#	Article	IF	Citations
37	Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia. Schizophrenia Research, 2013, 150, 323-324.	1.1	4
38	Assessment of transient dopamine responses to smoked cannabis. Drug and Alcohol Dependence, 2021, 227, 108920.	1.6	4
39	Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. Journal of Psychiatric Research, 2022, 147, 248-253.	1.5	4
40	Cannabis in psychiatric disorders: the cart before the horse?. Lancet Psychiatry,the, 2019, 6, 968-969.	3.7	2
41	Alterations in the Endocannabinoid System in Schizophrenia. Biological Psychiatry, 2020, 88, 675-677.	0.7	2
42	Medicalization of Marijuanaâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1931.	3.8	1
43	Exocannabinoids, Endocannabinoids, and Psychosis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 600-602.	1.1	0
44	Editorial. Psychopharmacology, 2022, , 1.	1.5	0